The company’s schedule begins with a presentation at Citi's 2026 Biopharma Back to School Conference on September 9 at 9:20 a.m. ET. One day later, on September 10, the executives will appear at the 2026 Cantor Global Healthcare Conference at 1:35 p.m. ET. Both sessions will be accessible via live webcasts through the investor relations portal on the firm’s website, with recordings remaining available for 90 days after each event.

Founded in 2018 by industry veteran David Hung, Nuvation Bio maintains operations across New York, San Francisco, Boston, and Shanghai. The firm focuses on developing drug-drug conjugates and targeted therapies for aggressive cancers, building on Hung’s previous work at Medivation, where he oversaw the development of prominent prostate cancer treatments.